Показано 0 из 0
Дата |
---|
21:49 |
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.72
|
1.98
|
1.91
|
1.72
|
1.97
|
1.95
|
|
|
38 492.15
|
181.00
|
|
2.58
|
1.83
|
1.71
|
1.83
|
1.73
|
|
|
15 414.16
|
114.00
|
1.94
|
2.34
|
2.035
|
1.86
|
2.06
|
1.87
|
|
|
24 593.27
|
136.00
|
2.04
|
2.11
|
2.19
|
1.995
|
2.20
|
2.005
|
|
|
31 478.08
|
151.00
|
2.07
|
2.67
|
2.17
|
2.04
|
2.22
|
2.18
|
|
|
22 048.83
|
71.00
|
2.04
|
2.67
|
2.25
|
2.13
|
2.295
|
2.145
|
|
|
7 480.01
|
76.00
|
2.07
|
2.44
|
2.20
|
2.06
|
2.27
|
2.25
|
|
|
11 299.23
|
101.00
|
2.15
|
2.56
|
2.11
|
2.11
|
2.30
|
2.27
|
|
|
16 762.07
|
75.00
|
2.05
|
2.11
|
2.31
|
2.07
|
2.31
|
2.07
|
|
|
15 116.49
|
237.00
|
2.26
|
2.34
|
2.40
|
2.23
|
2.43
|
2.27
|
|
|
27 279.16
|
147.00
|
Genelux Corporation operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from cancers, including solid tumors.